ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 279 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,661,421 | -34.0% | 175,692 | -24.1% | 0.01% | -40.9% |
| Q2 2023 | $5,543,490 | +83.1% | 231,461 | +43.9% | 0.02% | +57.1% |
| Q1 2023 | $3,027,102 | -20.9% | 160,845 | -33.1% | 0.01% | -46.2% |
| Q4 2022 | $3,828,298 | -99.9% | 240,471 | -8.6% | 0.03% | -23.5% |
| Q3 2022 | $4,304,741,000 | +50.8% | 263,126 | +29.8% | 0.03% | +30.8% |
| Q2 2022 | $2,855,366,000 | +47.1% | 202,652 | +152.9% | 0.03% | +62.5% |
| Q1 2022 | $1,940,482,000 | +56.7% | 80,119 | +51.1% | 0.02% | +77.8% |
| Q4 2021 | $1,237,976,000 | -3.4% | 53,041 | -31.2% | 0.01% | -10.0% |
| Q3 2021 | $1,281,395,000 | +48.9% | 77,146 | +118.6% | 0.01% | +42.9% |
| Q2 2021 | $860,674,000 | +54.0% | 35,288 | +160.4% | 0.01% | 0.0% |
| Q3 2020 | $558,937,000 | -32.3% | 13,550 | -20.4% | 0.01% | -46.2% |
| Q2 2020 | $825,298,000 | +227254.8% | 17,027 | +100.5% | 0.01% | +333.3% |
| Q4 2019 | $363,000 | +13.1% | 8,493 | -4.9% | 0.00% | 0.0% |
| Q3 2019 | $321,000 | – | 8,930 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |